Breast cancer patients using aromatase inhibitors. Prostate cancer patients undergoing androgen deprivation therapy. Cancer patients with a family history of osteoporosis.

Bone Health Assessment for Cancer Patients | Lahalak Medical Platform

Comprehensive bone density assessment for oncology patients on hormone therapy, focusing on early detection of osteoporosis to ensure skeletal strength and prevent fractures during the cancer recovery journey.

Scientific name: Bone Health Assessment for Oncology Patients (DEXA)

This procedure includes DEXA scans for bone mineral density and biochemical marker evaluations. It is essential for breast or prostate cancer patients on hormone-suppressing therapies to manage and mitigate bone loss risks.

Bone Health Assessment for Oncology Patients (DEXA) - Protect Your Bone Health During Treatment

Service type Diagnostic & Imaging

Duration 30-45 minutes

Fasting Fasting is not required

Included Services

DEXA Bone Density Scan
Calcium and Vitamin D Analysis
Biochemical Bone Marker Evaluation
Detailed Medical Report

Medical Service Information

Why is this assessment necessary?

Certain chemotherapy and hormone treatments cause rapid bone density loss.
Androgen deprivation therapy and aromatase inhibitors reduce skeletal strength.
The scan helps prevent fractures that could hinder cancer treatment progress.

Target Groups

Breast cancer patients using aromatase inhibitors.
Prostate cancer patients undergoing androgen deprivation therapy.
Cancer patients with a family history of osteoporosis.

Results and Follow-up

Determination of T-score to assess osteoporosis risk.
Medical recommendations regarding supplements or bone-strengthening medications.
Establishing a periodic follow-up schedule based on findings.

Conditions & Notices

Bring previous hormone therapy reports
Inform the technician of pregnancy or metal implants